We have shown recently that cell surface-bound, single-chain Fv antibodies (scFv) are a powerful tool for the improvement of cellular tumor vaccines. To simplify this approach and to develop a general tool for the generation and improvement of cellular tumor vaccines, we chose an scFv against a peptide from the human proto-oncogene c-myc that could anchor any c-myc-tagged protein to the cell surface. The retroviral vector p50-Mx-neo (pMESV) was used to express scFv on the surface of the human melanoma line SkMel63. The cell-bound anti-c-myc scFv bound specifically to a soluble purified anti-CD28 scFv carrying a c-myc peptide-tag at its C terminus. Proof of principle was determined by incubating human peripheral blood lymphocytes with a mixture of (a) anti-c-myc-transfected SkMel63 cells binding the anti-CD28 scFv and (b) SkMel63 cells transfected with an anti-CD3 scFv. A clear synergistic effect on T-cell activation was observed that was comparable with that obtained in previous studies using SkMel63 cells transfected with the gene for the anti-CD28 scFv. As the cell surface-displayed anti-c-myc scFv can bind any c-myc-tagged protein of interest, this technique facilitates the genetic engineering of cellular vaccines for the therapy of virtually all human neoplasias.
T he activation of T cells during an immune response requires the participation of two stimulatory signals.
A primary signal is provided by the engagement of the T-cell receptor/CD3 complex and a second signal is provided by costimulatory molecules (e.g., by the interaction of the CD28 receptor on the T-cell surface with the family of B7 costimulatory molecules). Activation of T cells in the absence of a costimulatory signal may result in an inability to produce interleukin-2 (IL-2), leading to anergy or apoptosis. 1, 2 The low immunogenicity of most cancer cells is often due to a lack of such costimulatory molecules necessary for effective T-cell stimulation. 3, 4 To facilitate the incorporation of any costimulatory molecule into tumor cell vaccines, we have stably expressed an anti-c-myc single-chain antibody (scFv) 5 on the surface of human melanoma SkMel63 cells. The anti-c-myc scFv carries a secretion signal peptide at its N terminus and a membrane-binding peptide at its C terminus for cell surface anchoring. To test the efficacy of this approach, we incubated SkMel63 anti-c-myc scFv cells with a soluble purified anti-CD28 5 scFv carrying the c-myc epitope EEQKLISEEDL at its C terminus. The anti-c-myc-transfected SkMel63 cells loaded with anti-CD28 scFv in combination with anti-CD3 scFv-transfected SkMel63 6 cells stimulated T-cell proliferation and induced tumor cell lysis in a synergistic manner. The results were comparable with our previous findings using a mixture of SkMel63 cells expressing anti-CD3 with SkMel63 cells expressing anti-CD28 scFv for the specific activation of T cells. 6 The present study has focused on the ability of anti-c-myc-transfected SkMel63 cells to bind a c-myctagged anti-CD28 scFv on their surface to provide a second signal for the activation of human peripheral blood lymphocytes (PBLs). However, this approach provides a general tool for the easy and effective ex vivo genetic improvement of cellular tumor vaccines with any c-myc-tagged protein for the clinical treatment of human neoplasia.
MATERIALS AND METHODS

Eukaryotic expression vector
The gene coding for the anti-c-myc scFv was cloned from the vector pOPE52 5 into the retroviral expression vector pMESV as described previously. 7 This was achieved by first removing the C-terminal c-myc epitope from the scFv gene in pLOPP2 anti-Y1 using 10 pmol of each primer (forward, 5Ј-CAAGT-TCAGCTGCAGG-3Ј; reverse, 5Ј-CCCCAGATCTTCGGATC-CAGTTGGTGC-3Ј), 2.5 M deoxynucleoside triphosphates (New England Biolabs, Schwalbach, Germany), and 1 U Vent-Polymerase (NEB) for 30 cycles and an annealing at 56°C for 1 minute. These primers introduce a PvuII site to the N-terminal end of the serum "A" sequence and a BglII site to the N-terminal end of the c-myc epitope, respectively. The amplified product was purified with the QiaQuick polymerase chain reaction purification kit (Qiagen, Hilden, Germany), digested with BglII, and ligated to obtain pLOPP2 anti-Y1 coding for the scFv without a C-terminal c-myc epitope.
Cell culture
The human melanoma cell line SkMel63 (kindly supplied by Dr. A. Knuth, Nordwest-krankenhaus, Frankfurt, Germany) was maintained in Dulbecco's modified Eagle's medium (Sigma, Deisenhofen, Germany) supplemented with 10% heatinactivated fetal calf sera (FCS) (PAA Laboratories, Linz, Austria), 100 U/mL penicillin, 100 g/mL streptomycin, and 2 mM L-glutamine (all from Seromed, Berlin, Germany) at 37°C in a humidified 5% CO 2 air atmosphere. SkMel63 cells were stably transfected with 20 g of EcoRI-linearized pMESV anti-c-myc scFv construct using the polylysine/DNA transfection method as described previously. 8 The cells were selected in 1 mg/mL G418 for 14 days, and resistant cells were cloned by limiting dilution. The stable anti-CD3 and anti-CD28 scFv SkMel63 transfectants have been described elsewhere. 6 
Immunofluorescence staining
The intracellular presence of anti-c-myc scFv was visualized by indirect immunofluorescence. The cells were grown on 8-well multitest slides (INC Biomedicals, Eschwege, Germany), washed with phosphate-buffered saline (PBS), and fixed with PBS/2% formaldehyde for 30 minutes. Then cells were permeabilized with PBS/1% Triton X-100 for 10 minutes, washed three times in PBS, and incubated in PBS/20% FCS for 30 minutes. All steps were performed at room temperature (RT). Afterward, cells were stained with rabbit serum A, which recognizes the N-terminal epitope of secreted scFv, 9 diluted 1/100 in PBS/20% FCS for 1 hour at 37°C, and washed three times in PBS. Development was performed for 45 minutes at 37°C with fluorescein isothiocyanate-conjugated, affinity-purified goat anti-rabbit immunoglobulin G (IgG) (Jackson ImmunoResearch, West Grove, Penn) diluted 1/200 in the same buffer. After washing three times in PBS, photographs were taken using a Zeiss Axiophot fluorescence microscope (Zeiss, Jena, Germany) and Ektachrome film (Kodak, Rochester, NY).
Analysis of cell surface expression
A total of 3 ϫ 10 5 cells/well were cultured in triplicate in 96-well, flat-bottom plates (Falcon, Meylan, France) for 1 day at 37°C, washed three times with serum-free medium, and incubated with soluble purified anti-CD28 scFv diluted in serum-free medium. Then cells were washed three times with complete culture medium, washed twice with PBS, and fixed with PBS/2% formaldehyde for 30 minutes at RT. Subsequent quantification of anti-CD28 scFv bound to cells was carried out by a conventional enzyme-linked immunosorbent assay (ELISA). The plates were blocked with PBS/20% FCS for 30 minutes at RT and incubated with serum A diluted 1/3000 in the same buffer for 1 hour at 37°C. After washing three times with PBS/0.075% Tween 20, the plates were incubated with 1/2000 peroxidase-conjugated, affinity-purified goat anti-rabbit IgG (Dianova, Hamburg, Germany) for 30 minutes at 37°C. Then plates were washed three times with PBS/0.075% Tween 20 and twice with PBS. Development was performed with 3,3Ј,5,5Ј-tetramethylbenzidine substrate (Kirkegaard and Perry, Md) and H 2 O 2 (1:1). Three individual experiments were carried out in triplicate, and the measurements were corrected by subtracting data obtained using cells cultured only with secondary antibody (Ab).
Cell proliferation assay
Untransfected SkMel63 cells as well as those transfected with anti-CD3, anti-CD28 scFv, or anti-c-myc scFv were ␥-irradiated (150 Gy). A total of 3 ϫ 10 5 cells of each transfectant were then incubated with 100 L of serum-free medium either alone or containing 1 g/mL soluble anti-CD28 scFv for 1-2 hours. The cells were washed with complete culture medium and PBS and added in triplicate to 96-well, round-bottom microtiter plates (Greiner, Solingen, Germany) at a density of 1 ϫ 10 5 cells/well. Cells were then mixed with 5 ϫ 10 4 PBLs obtained from an allogeneic healthy donor (human leukocyte antigen-A*0201) as described previously. 10 All steps were performed at 4°C. After incubation overnight at 4°C, cells were grown at 37°C for 5 days and then pulsed with 1 Ci 
Flow cytometry analysis
PBLs were grown in 24-well plates (Falcon) under the same conditions as described above. First, they were collected and incubated at 4°C for 1 hour with 50 L of anti-transferrin receptor (TnR) monoclonal Ab (mAb) (OKT9). The cells were then washed three times with PBS and incubated with fluorescein isothiocyanate-conjugated, affinity-purified goat antimouse IgG (Amersham International, Little Chalfont, UK) diluted 1/5000 for 30 minutes at 4°C. Subsequently, cells were washed again and suspended in PBS containing 0.5 g/mL propidium iodide (Sigma) to exclude dead cells. The fluorescence intensity corrected for that of PBLs incubated under the same conditions but without primary Ab was determined using a flow cytometer (Coulter, Palo Alto, Calif) for three independent experiments.
Analysis of human cytokine production
Cytokine production by stimulated PBLs was determined by flow cytometric analysis. The cytokines were assayed by intracellular staining according to the manufacturer's instructions using carboxyfluorescein-conjugated mAb against human interferon-␥ (hIFN-␥) or human IL-4 (hIL-4) (R&D Systems, Wiesbaden, Germany). The fluorescence intensity was corrected for that of PBLs incubated under the same conditions but with carboxyfluorescein-conjugated IgG1 or IgG2b mAb.
Cytotoxicity assay
The cytolytic activity of human PBLs was detected by a DNA fragmentation assay as described previously, 11 but with some modifications. Target cells (untransfected SkMel63 cells) were added to 96-well, round-bottom microtiter plates at a density of 1 ϫ 10 5 cells/well, pulsed with 1 Ci [ 3 H]thymidine, and incubated at 37°C for 4 hours. Cells were washed five times with PBS and incubated in triplicate for 4 -5 hours at 37°C in complete culture medium alone (control cells) or with human PBLs that had been activated for 5 days, as described above. Other control cells (without coincubation with PBLs) were incubated in culture medium alone under the same conditions to evaluate their viability. They were washed again and incubated with PBS/0.2% Triton X-100 for 30 minutes at 4°C. The plate was centrifuged, and the radioactivity present in the supernatant (fragmented DNA) and pellet (intact DNA) was determined by liquid scintillation counting. The percentage of DNA fragmentation was obtained from the ratio of fragmented to total DNA. Data from control cells incubated with PBS/0.2% Triton X-100 were considered in all calculations and were very similar to the data obtained for control cells not incubated with this buffer. Three individual experiments were performed in triplicate.
RESULTS
Analysis of cell surface expression of the anti-c-myc scFv: Antigen binding and stability To select transfected SkMel63 melanoma cells, we detected the intracellular expression of anti-c-myc scFv by indirect immunofluorescence. The cells were fixed, permeabilized, and incubated with serum A, which recognizes the N-terminal epitope of secreted scFv on Western blots. 9 A strong fluorescence appeared to be associated with membranes of the endoplasmic reticulum surrounding the nucleus. No fluorescence was detected with untransfected SkMel63 cells (data not shown).
The expression of a functional anti-c-myc scFv on the surface of transfected SkMel63 cells was analyzed by a conventional quantitative ELISA. The anti-c-myc SkMel63 transfectant was incubated at 37°C for 1 hour with various amounts of a soluble anti-CD28 scFv carrying an exposed C-terminal c-myc epitope. Untransfected SkMel63 cells and SkMel63 cells transfected with an anti-CD3 scFv 6 were used as controls. A significant binding of soluble anti-CD28 scFv to the surface of anti-c-myc-transfected cells was observed. Very little anti-CD28 scFv was detected on either the untransfected or the anti-CD3 SkMel63 cells (Table 1 ). This indicates that the anti-cmyc scFv was not only present on the cell surface but that it could also bind its antigen.
To determine the binding stability of the anti-CD28 scFv to the tumor cell surface, untransfected SkMel63 cells as well as the anti-c-myc and the anti-CD3 SkMel63 transfectants were incubated with 1 g/mL of anti-CD28 scFv for 1 hour at different temperatures. The cells were then washed and incubated at the same temperatures for different time periods. In all cases, the anti-CD28 scFv displayed the best binding to the cell surface of the anti-c-myc-transfected cells. Moreover, when the anti-cmyc-transfected cells were incubated at RT or at 4°C for 24 hours, a relatively little loss of binding occurred (Table 2) .
Human PBLs are stimulated to proliferate by anti-cmyc scFv SkMel63-transfected cells bound to anti-CD28 scFv To test the ability of the anti-c-myc SkMel63-transfected cells loaded with anti-CD28 scFv to provide a second signal for the induction of lymphocyte proliferation, these cells were mixed with anti-CD3-transfected SkMel63 cells and incubated for 3 days with allogeneic human PBLs in the absence of exogenous cytokines (first stimulation). The PBLs were then removed, further incubated alone without any stimulation for 5 days, and finally incubated again with the SkMel63 transfectants for 2 days (second stimulation). As a positive control, a mixture of SkMel63 cells expressing the anti-CD3 scFv with SkMel63 cells expressing the anti-CD28 scFv was incubated with the PBLs under the same conditions. Untransfected SkMel63 cells, as well as the different SkMel63 transfectants alone, did not give rise to a significant increase in lymphocyte proliferation. However, a marked synergistic proliferation was obtained when anti-CD3 and anti-CD28 scFv-transfected melanoma cells were cocultured with PBLs, in accordance with our previous observations. 6 A comparable synergistic effect on T-cell proliferation was observed when anti-c-myc SkMel63-transfected cells loaded with the anti-CD28 scFv and the anti-CD3 transfectants were cocultured with human PBLs. This costimulatory effect was not observed when the same cell combination was used without loading the anti-c-myc-transfected SkMel63 cells with the soluble anti-CD28 scFv (Fig 1) .
Anti-c-myc-transfected SkMel63 cells induce production of IFN-␥
To investigate the activation of human T lymphocytes in response to a 5-day incubation with the different SkMel63 transfectants, the expression of TnR and the production of hIFN-␥ and hIL-4 were traced by flow cytometry. We performed an intracellular cytokine secretion analysis because this technique permits an analysis of the cytokine secretory pattern of individual cells within a mixed population, in contrast to a conventional sandwich ELISA, which shows the average value for the entire population of cells. 12 Significant T-cell activation as monitored by TnR expression, and hIFN-␥ production was shown for the incubation of PBLs with anti-CD3 and anti-CD28 SkMel63 transfectants (Table 3) . Comparable results were achieved when human PBLs were incubated with the anti-CD3 transfectants and anti-c-myc transfectants that had been preincubated with anti-CD28 scFv (Table 3) . Practically no hIL-4 production was found in any of all the samples (data not shown), suggesting that a predominantly T helper 1-type response had occurred. Little T-cell activation and hIFN-␥ production was observed when PBLs were incubated with either untransfected SkMel63 cells or one of the SkMel63 transfectants alone.
Anti-c-myc-transfected SkMel63 cells induce cytolytic activity of human PBLs
To test whether the anti-c-myc scFv-transfected SkMel63 cells were able to induce cytolytic activity in PBLs, DNA 6 and 12) . The effector to target ratio assayed was ϳ1:2. Data (ϮSD) were corrected by subtracting counts per minute from PBLs cultured alone. 
*SkMel63 cells were incubated with 1 g/mL soluble anti-CD28 scFv for 1 hour at different temperatures. The cells were then washed and incubated for different times in culture medium at different temperatures. The binding stability of anti-CD28 scFv to the cell surface was analyzed by ELISA (see Materials and Methods).
†Fluorescence intensity of SkMel63 cells carrying anti-CD28 scFv considering the absorbance at 655 nm to be 100 arbitrary units from cells incubated with medium alone. This was ϳ 0.12 Ϯ 0.002 in all cases. Results of one representative experiment of three are shown. Preincubation of these anti-CD3 and anti-CD28 transfectants with soluble anti-CD28 scFv had little effect on the amount of DNA fragmentation. However, a similar level of DNA fragmentation was observed using PBLs incubated with both anti-c-myc-transfected cells loaded with anti-CD28 scFv and the anti-CD3 SkMel63 transfectant (Fig 2) .
DISCUSSION
We have shown recently that a combination of cells displaying anti-CD3 scFv with cells displaying anti-CD28 scFv provides a powerful tool for the activation of T cells. The synergistic effect of these cells on T cells resulted in the specific lysis of untransfected tumor cells. To design a more generalized approach for the ex vivo genetic improvement of a cellular tumor vaccine, we expressed anti-c-myc scFv on the surface of human tumor cells that is able to bind any recombinant effector molecule of interest carrying the c-myc marker peptide. In a previous generalized approach designed to attach costimulatory molecules, we used a biotinylated scFv against hemagglutinin-neuraminidase from the envelope of Newcastle disease virus to couple streptavidin-linked molecules. Although the Newcastle disease virus-infected cells did bind the Ab conjugate, 13 a disadvantage was the requirement for several components. In a second generalized approach, an anti-phOx scFv was displayed on the cell surface. Immunomodulatory factors and other chemically modified ligands can easily be conjugated with the hapten phOx and afterward be attached to the cell surface-bound anti-phOx scFv. 7 Anti-CD3, anti-CD28, and anti-CD5 mAb coupled to the phOx antigen were shown to bind to the surface of anti-phOx-transfected cells and synergistically induce the proliferation of allogeneic human PBLs.
14 However, these studies revealed the necessity for further simplification, because the practical use of genetically enhanced cellular tumor vaccines in a clinical setting depends upon the development of relatively facile methods.
In the present study, we have shown that an anti-c-myc scFv-transfected SkMel63 melanoma cell is able to specifically bind a soluble anti-CD28 scFv carrying a Cterminal c-myc peptide tag. However, as shown in Table  1 , no large differences in the binding of the anti-CD28 scFv were observed between the anti-c-myc and the anti-CD3 SkMel63 transfectants. Because the human melanoma cell line SkMel63 used in these studies expresses little, if any, CD80 (B7.1) and CD86 (B7.2) ligands to the CD28 receptor, 10, 15 these results probably reflect a low expression level of anti-c-myc scFv molecules on the tumor cell surface together with some unspecific binding and lack of binding of the anti-CD28 scFv to CD28 ligands.
Unspecifically bound scFv appeared to have no significant effect on T-cell activation, because only the anti-cmyc-transfected SkMel63 cells incubated with anti-Cd28 scFv were able to synergistically induce high lymphocyte proliferation in combination with the anti-CD3 scFvtransfected cells (Fig 1) . These results are comparable with our previous studies, in which a mixture of cells expressing anti-CD3 scFv with cells expressing anti-CD28 scFv resulted in marked synergistic proliferation and activation of allogeneic human PBLs in vitro. 6 The activation of T cells can be monitored by measuring hIFN-␥ production and TnR expression. hIFN-␥ is known to be a potent multifunctional cytokine secreted by activated natural killer cells and CD4 ϩ and CD8 ϩ T cells. 16 It can up-regulate a number of lymphoid cell functions, including antitumoral responses of natural killer and cytotoxic T lymphocytes, and can exert strong regulatory effects on subsets of B and T cells. The TnR is expressed in activated CD4 ϩ and CD8 ϩ T lymphocytes. Using these markers, significant activation was only observed when the PBLs were incubated with the anti-c-myc-transfected cells loaded with anti-CD28 scFv together with the anti-CD3 SkMle63 transfectant (Table 3) . Moreover, only these PBLs had effective 11) , or anti-CD3 and anti-cmyc SkMel63 transfectants (lanes 6 and 12) and analyzed for induction of DNA fragmentation. SkMel63 cells were incubated previously with serum-free culture medium with (ϩ) or without (Ϫ) 1 g/mL of anti-CD28 scFv for 1 hour at 4°C. The ratio of fragmented DNA in SkMel63 control cells (without incubation with human PBLs) was 0.01 Ϯ 0.003 and was considered to be 100%. The effector to target ratio was ϳ1:2. Data (ϮSD) were corrected by subtracting data from PBLs cultured alone.
cytolytic activity and induced significant DNA fragmentation in untransfected SkMel63 cells (Fig 2) .
Our results provide valuable information for the application of the anti-c-myc scFv in genetically enhanced immunotherapy of cancer. Cells stably transfected with the gene coding for an anti-c-myc scFv fused to a membrane binding domain can specifically bind any protein carrying the 10-aa epitope peptide without the need for any chemical modifications. Similar to the suggestions of previous authors using B7.1, 17 we propose that the creation of a bank of different human tumor cell lines stably expressing the anti-c-myc scFv molecules could provide a general and effective means for (a) the ex vivo induction of specific T cells for adoptive immunotherapy or (b) the generation of cellular tumor vaccines.
